Breaking AI & Tech News Analyzed

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”

GSK has revealed promising early results for its treatment for gynaecological cancers, Mocertatug Rezetecan (Mo-Rez), as its chief executive, Luke Miels, seeks to speed up drug development at the group.The company reported that in an early-stage trial, Mo-Rez shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.GSK acquired the Mo-Rez cancer treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharma in late 2023, and has trialled it in 224 patients around the world, including the UK, over the past year. Few patients needed to stop treatment because of side-effects, the most common being nausea. It is administered every three weeks via intravenous infusion.Combined with data from a separate, intermediate trial in China, these results give GSK the confidence to go straight to late-stage trials, with five clinical studies planned globally in the next few months, including on patients in the UK.Presenting the results at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Puerto Rico, Hesham Abdullah, GSK’s global head of cancer research and development, said: “Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates. With Mo-Rez we now have compelling evidence of a promising clinical profile.”Endometrial cancer affects 1.6 million women globally, with 417,000 new cases each year. Ovarian cancer affects 843,000 people, with 240,000 new cases annually.Abdullah described Mo-Rez as a “key asset” in the company’s growing cancer portfolio, expected to be a blockbuster drug with peak annual sales of more than £2bn, which GSK hopes will help it achieve its 2031 sales target of £40bn.

Israel's ongoing attacks on Lebanon have led to a significant deterioration of the country's healthcare infrastructure. In the past month, 53 medical workers have been killed, 87 ambulances and medical centers destroyed, and five hospitals forced to close, according to Lebanon's Ministry of Public Health.The attacks have resulted in the displacement of 1.2 million people, putting an enormous strain on the already struggling Lebanese healthcare system. Experts and analysts say that Israel's actions are part of a broader strategy to force people out of southern Lebanon.“Israeli strikes and blanket evacuation orders are cutting people off from care and shrinking the space for health services to function,” said Luna Hammad, Lebanon medical coordinator for Doctors Without Borders (MSF). MSF has documented a pattern of attacks affecting healthcare.The destruction of healthcare infrastructure has also led to a significant increase in emergency room admissions. Healthcare facilities are under higher strain than before, with many patients needing treatments like chemotherapy, radiotherapy, and dialysis being transferred further north.Direct attacks on healthcare workers and facilities have been documented by Human Rights Watch (HRW), which has noted repeated, apparently deliberate attacks on medical workers in Lebanon. Medical workers and healthcare facilities are protected under international humanitarian law, and Israel's attacks on medics in 2024 were described as an apparent war crime by HRW.The attacks on healthcare infrastructure during times of war are not new. Forensic Architecture has documented systematic targeting of hospitals and healthcare workers in Gaza. Experts warn that such attacks have compounding effects, including treatable injuries getting worse, war wounds not healing properly, and long-term consequences.Experts and analysts say that the attacks are unlikely to cease as long as the pattern of impunity continues. Lebanon's government has a responsibility to ensure accountability and to give jurisdiction to the International Criminal Court (ICC) to investigate and prosecute war crimes.